AGA. A. Gvozdev

A. A. Gvozdev

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


A. A. Gvozdev has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Isolated leptomeningeal relapses in high-risk neuroblastoma

    by A. N. Turchina, D. Yu. Kachanov, N. A. Andreeva, D. T. Utalieva, R. A. Moiseenko, I. V. Sidorov, D. M. Konovalov, M. E. Dubrovina, A. A. Gvozdev, T. V. Shamanskaya

    Background. Neuroblastoma (NB) is the most common extracranial solid malignant tumor of childhood, about 50 % of patients with NB are stratified into a high-risk (HR) group at the time of diagnosis. Despite the multimodal approach to therapy, half of the patients develop relapse of the disease, affecting mostly bones and bone marrow. Relapses with localization in the central nervous system (CNS) are extremely rare and are predominantly parenchymal in nature. Isolated leptomeningial involvement at relapse is an incredibly rare (0.6 % of all relapses), but is characterized by extremely aggressive manifestation and associated with unfavorable prognosis.Materials and methods. A description of three clinical cases of CNS relapses with isolated leptomeningeal lesions in patients with HR NB treated at Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia.Results. The study included 3 patients with isolated leptomeningeal relapse of NB. The age at the time of the initial diagnosis was 23, 36, and 80 months. Initially, the patients were stratified into a HR group according to the GPOH NB-2004 protocol. Amplification in the MYCN gene was detected in two patients, gain MYCN in one; deletion of the 1p chromosomal region was also detected in two patients, and deletion of the 11q chromosomal region in one patient. Two patients had a mutation in the ALK gene: in one case, the mutation was found in the primary tumor tissue, in the other – in the relapse tumor tissue. The time from the initial diagnosis to the detection of leptomeningeal recurrence of the disease was 5, 15 and 16 months. In two cases, CNS relapse debuted with the appearance of clinical symptoms, in one case it was detected during a follow-up examination. All patients received anti-relapse therapy with drugs that penetrate the blood-brain barrier, two received molecular-directed therapy with ALK inhibitors, and only one patient received craniospinal irradiation and intrathecal administration of a chemotherapy drug.Two patients died as the disease progressed. One patient is alive at the time of the publication without disease progression, the follow-up time is 9 months from the diagnosis of relapse.Conclusions. Leptomenigial CNS lesion in relapse NB may be characterized by a non-specific clinical presentation requiring a differential diagnosis with the toxicity of therapy. Comprehensive therapeutic approach with chemotherapy, radiation therapy, and intrathecal administration of drugs is needed to improve the long-term survival of this subgroup of patients.

  • Open Access

    Rare embryonic tumor of the central nervous system – neuroblastoma with FOXR2-activation

    by E. V. Kumirova, S. S. Ozerov, M. V. Ryzhova, D. M. Konovalov, A. P. Shekhtman, V. V. Emtsova, Yu. V. Vyazova, M. M. Andrianov, E. V. Abbasova, A. A. Gvozdev, et al.

    Introduction. The development of technologies for molecular genetic typing of tumors of the central nervous system (CNS) has significantly increased the specificity of traditional histological and immunohistochemical research methods. As a result, completely new variants of tumors have appeared, as well as improved results of treatment of tumors with a long-term favorable prognosis. Thanks to new biomarkers, among morphologically similar small-cell embryonic CNS tumors, extremely rare tumors have been identified: ETMR (embryonic tumor with multiple rosettes C19MC), CNS NB-FOXR2 (CNS neuroblastoma (NB) with FOXR2-activation), CNS EFT-CIC (tumor of the CNS sarcoma family of sarcoma alteration), CNS HGNET-MN1 (neuroepithelial tumor of the CNS of high grade with MN1 alteration), CNS HGNET-BCOR (neuroepithelial tumor of the CNS of high grade with BCOR alteration).The aim of the study was to assess the historical prerequisites for the emergence of a new rare nosological form “CNS NB with FOXR2- activation”, as well as presentation of own results of diagnostics and treatment of children with this tumor.Materials and methods. The results of diagnosis and treatment of 7 patients with CNS NB with FOXR2-activation were studied. Tumor identification was carried out using a new DNA methylation technique for CNS tumor profiles using the Heidelberg (Germany) brain tumor classifier (www.molecularneuropathology.org), which has recently become available in Russia.Results and discussion. Based on a review of international experience, the evolution of the appearance in the classification of CNS tumors, as well as the clinical and molecular features of CNS neuroblastoma with FOXR2-activation are presented. The authors present their own results of diagnostics and treatment of 7 patients with a rare tumor CNS neuroblastoma with FOXR2-activation.Conclusion. Biomarkers have been proposed for the differential diagnosis of small-cell PNET-like tumors of the CNS in children. Due to the molecular identification of this tumor in children, it became clear that such patients, provided that the treatment protocol is adequately followed, have quite satisfactory long-term survival results.